Little is known about the factors controlling somatostatin secretion in man, and data are not available on the changes in circulating levels in various human physiological or pathophysiological states. This is mainly a consequence of the technical difficulties involved in measuring somatostatin in plasma. In the presence of plasma, binding of somatostatin tracer to antibody was consistently decreased by about 20 %, and this could not be abolished by the addition of EDT A and aprotinin or by the use of specially prepared somatostatin-free plasma. Furthermore, in the presence of plasma, endogenous somatostatin does not dilute in parallel with synthetic cyclic somatostatin standard.
plasma was 78 %.
The fasting level of immunoreactive somatostatin at 0900 hours in 40 normal subjects ranged from 17 to 81 pgjml. Care is needed, however, when comparing these values with those obtained from other laboratories since standard preparations of somatostatin vary considerably in their immunopotency.
The first evidence for a hypothalamic factor in-immunocytochemistry and radioimmunoassay hibiting growth hormone release from the pituitary to be used to study the distriwas obtained in the rat by Krulich et al. (1968) . In bution of somatostatin in the brains of experimental 1973 a polypeptide was isolated from ovine hypo-animals. Pelletier et al. (1974) , using immunothalami which suppressed growth hormone secretion cytochemical techniques, found somatostatinboth in vitro and in vivo in rats (Brazeau et al., 1973) positive granules in nerve endings of the external and in man (Hall et al., 1973; Mortimer et al., 1974) . zone of the median eminence, and these findings have This cyclic tetradecapeptide with a molecular been confirmed by radioimmunoassay (Arirnura weight of 1639 daltons has been variously called Brownstein et al., 1975) . growth hormone-release inhibiting hormone, somaSignificant quantities of somatostatin have also totrophin release inhibiting factor, or somatostatin. been found in extrahypothalamic areas of the brain, It has also been isolated from porcine and human and the hormone has been localised by immunohypothalami Aubert et al., cytochemistry in peripheral nerve endings of the rat 1977). The hormone itself has been synthesised and guinea-pig (Hokfelt et al., 1975; (Brazeau et al., 1973; Coy et al., 1973) , and synthesis 1977) where it may act as a neurotransmitter (Luft of a tyrosinyl analogue, together with the production et al., 1978) . Tn addition to its actions in suppressing of rabbit antisomatostatin serum, has allowed growth hormone secretion in man, thyroid stimu-lating hormone (TSH) secretion is also inhibited (Hall et al., 1973) . It has a number of actions outside the pituitary in man, which include inhibition of the secretion of insulin (Alberti et al., 1973; Mortimer et al., 1974) , glucagon (Mortimer et al., 1974) , gastrin and gastric acid (Bloom et al., 1974) , cholecystokinin-pancreozymin (Schlegel et al., 1977) , gastric inhibitory peptide, and motilin Pederson et al., 197:'5) . It suppresses renin secretion (Gomez-Pan et al., 1970; Rosenthal et al., 1976) . It is also known to be present in the pancreatic D cells as well as in other areas of the gut of several species including man (Luft et al., 1974; Polak et aI., 1975) where it may have a paracrine role.
Several radioimmunoassays for somatostatin have been described previously (Arirnura et 01., 1975; Kronheim et al., 1976; Epelbaum et al., 1977; McIntosh et al., 1978; Patel and Reichlin, 1978) . Although these assays have been satisfactory for studying somatostatin distribution in different tissues, only one group has reported plasma levels in man Kronheim et al., 1978) . This probably reflects the technical difficulties encountered during attempts at assay resulting from interference by substances in plasma, including binding proteins, or enzymic degradation of somatostatin tracer, which may occur during incubation.
While considerable work has been done on the in vivo effects of the administration of exogenous somatostatin (Gomez-Pan and Hall, 1977; Mortimer, 1977) , little has been published on the factors controlling its secretion in health and disease since blood levels have been so difficult to measure. Abnormal secretion could underlie a number of endocrine diseases, including acromegaly and diabetes mellitus. In experimental insulin-deficient diabetes mellitus there is hyperplasia of somatostatincontaining pancreatic D cells (Orci et al., 1976) , and in diabetic dogs secretion of this peptide may be abnormal . Furthermore, it is possible that maturity-onset diabetes is a consequence of somatostatin deficiency . Somatostatin acting as a chemical messenger may therefore be a true hormone, a peptidergic neurotransmitter, or a paracrine hormone in the gut.
For these reasons we have developed a specific radioimmunoassay for somatostatin sufficiently sensitive to be used in physiological studies. We report a detailed description of the assay, the problems encountered during the attempt to establish an unextracted assay, and a new method of labelling and purifying the tracer.
Material and methods

SOMATOSTATIN
Cyclic somatostatin, and tyrosine-l and tyrosine-l l Erica Penman et al.
somatostatin for iodination were obtained from Sachem Inc, California. The former was used as standard throughout and stored at -70°C in 0·05 M sodium phosphate buffer, pH 7-4, containing 0·5 % human serum albumin (HSA) (Blood Products Laboratory, Lister Institute, Elstree, Herts) (concentration, 100 ngjrnl) until used.
ANTIBODY
Somatostatin antiserum was prepared as follows:
Preparation of antigen Cyclic somatostatin, I mg, Giant Keyhole Limpet haemocyanin, 5 mg (Calbiochern, Los Angeles, USA), and 1,3 diethyl carbodiimide, 0·24 mg (Sigma, St Louis, Missouri, USA) were dissolved in 360 /-'1 of normal saline and incubated with gentle stirring for 18 hours. This procedure is a modification of the method described by Skowsky and Fisher (1972) for coupling peptides.
IMMUNISATION PROCEDURE
The above mixture was diluted in 0·9% NaCI containing 5 rng/rnl of heat-killed Mycohacterium tuberculosis (Difco Laboratories, Detroit, Michigan, USA) to give a concentration of 100 /-,g of somatostatin/ml, To this solution an equal volume of complete Freund's adjuvant (Difco Laboratories) was added to give a final somatostatin concentration of 50 /-,g/ml. Each rabbit received 2 ml of the antigen mixture injected intradermally along the back at 30-40 separate injection sites. At an independent site each animal received 0·5 ml of adsorbed diphtheria, tetanus, and pertussis vaccine (Wyeth, Marietta, Pennsylvania, USA). The animals were boosted every four weeks until significant titres developed and at six-week intervals thereafter. This procedure is a modification of that described by Vaitukaitis et al. (1971 Kabi, Stockholm, Sweden), and Serono somatostatin (Dr Harrant, Serono Institute Pharmacologica, Rome, Italy). These preparations were obtained specifically for the assay characterisation and were used shortly after receipt.
PREPARATION OF LABELLED SOMATOSTATIN
Since somatostatin has neither a tyrosine nor a histidine residue it is necessary to use a tyrosinated analogue of the hormone for iodination. We compared two of these analogues: 1Tyr-somatostatin and IlTyr-somatostatin. For each analogue two different iodination techniques and two methods of purifying the iodinated peptide were compared.
Chloramine-T iodination
The method used was a modification of the Hunter and Greenwood (1962) method with the omission of the metabisulphite step. To 2·5 iLg of Tyrsomatostatin in IO iLl 0·005 M HCl in a polystyrene vial were added 10 iLl0'5 Msodium phosphate buffer, pH 7'4, I mCi Na 125I (Radiochemical Centre, Amersham) and 5 iLg chloramine-Tin 0'05 M sodium phosphate buffer, pH 7·4. After 20 seconds the reaction was terminated by the addition of I ml of 0·05 M sodium phosphate buffer containing 100 iLg HSA. The reactants were then loaded onto the purification column.
Lactoperoxidase iodination
Lactoperoxidase (Calbiochem, Los Angeles, USA) was conjugated to poly maleic anhydride (Merck 10272, Darmstadt, Germany) by the method of Karonen et al. (1975) . For iodination 30 iLl 0·5 M sodium phosphate buffer, pH 704, was added to 2· 5 iLg of Tyr-somatostatin in IO iLl 0·005 M HCI, followed by I mCi Na l25 1, 3 iLg lactoperoxidase, and 5 iLlof 0·0003 % solution of H202. The reactants were incubated at room temperature for one hour with intermittent mixing, and the reaction mixture was then diluted with 200 iLl of 0·1 M sodium phosphate buffer, pH 704, + 600 iLl H20. After centrifugation (2500 rpm for IO minutes) the supernatant was loaded onto the column for purification.
PURIFICATION ON CMC CELLULOSE
A 3 x 0·8 cm column of CMC cellulose (CM 52, Whatman, UK), pH 4,6, was equilibrated in a 2-ml syringe with 10 mM ammonium acetate (NH4Ac), pH 4,6, and primed with I mg of polypeptide (Sigma, St Louis, Missouri, USA) in I ml 10 mM NH4Ac. The polypeptide was eluted with 1 mil M NH4Ac and the column was re-equilibrated with 10 rnl of 10 mM NH 4Ac. The iodination mixture was applied to the column and the iodide peak was eluted with 10 mM NH4Ac. Material which probably represented damaged peptide was eluted with 0'2 M NH4Ac, and iodinated Tyr-somatostatin was eluted with 004 M N H4Ac.
PURIFICATION ON OCTADECA SILYL(ODS)
SILICA This is a modification of the method of Bennett et al. (1977) . A I x 0·5 ern column of Spherisorb (10 micron ODS Silica, Phase Separations, Clwyd, UK) was primed with I mg of polypeptide and washed with 80 % methanol and 1% TFA. After equilibration with 1% TFA in water the iodination mixture was loaded onto the column and washed with 800 iLl of increasing concentrations of methanol containing 1% TFA to elute 125J-Tyr-somatostatin.
These purified tracers were diluted 1 in 10 in 0·05 M sodium phosphate buffer, pH 7-4, containing 20 mg/rnl polypeptide and stored at -70 cC.
Assay procedure UNEXTRACTED SOMATOSTATIN ASSAY Standard curves were constructed using doubling dilutions of somatostatin in the range 9-1250 pgjmJ. Each tube contained 100 iLl of standard, to which was added sequentially 200 iLl diluent buffer (0'05 M sodium phosphate buffer containing 0'25% EDTA, 0'5% HSA, and 0'02%'sodium azide), 100 iLl antiserum at a final dilution of 1 :150 000 (at which dilution 45 % of the tracer is bound in the absence of unlabelled peptide), and 100 fLl tracer containing 4 pg 125I-llTyr-somatostatm. Separation of bound from free 125I-llTyr-somatostatin was carried out by double antibody precipitation using a final dilution of anti-rabbit y-globulin (Wellcome) of 1:224 and a 1:1400 dilution of carrier rabbit serum (Wellcome). Diluent buffers of different pH (6'3, 7'0, 7'4, 8,6) and protein concentration (0·25 %, 0·5 %, 1 % HSA) were compared. A range of incubation conditions was also tested using simultaneous addition of antibody and tracer with a total incubation time of 24 or 48 hours before adding second antibody, and using 24 hour delayed addition of tracer with a total incubation time of 48 or 72 hours before adding second antibody. Standard curves were constructed in buffer and in somatostatin-free plasma (see below) with and without the addition of aprotinin (Trasylol; Bayer UK Ltd, Haywards Heath, Sussex, UK) and EDTA.
PREPARATION OF SOMATOSTATIN-FREE PLASMA Anti-somatostatin antibody was precipitated from 200 ,...1 of neat antiserum by addition of 85 ,...1 of a saturated solution of ammonium sulphate (to give a final concentration of 30 %) and was left for one hour at 4°C. The solution was centrifuged at 10 000 rpm for 30 minutes, and the precipitate was dissolved in 1 ml of 0·1 M sodium bicarbonate and dialysed against 2L of 0·1 M sodium bicarbonate for 48 hours at 4°C with one change of buffer. The dialysate contained 4 mg of protein (assuming E~~!i'~1 mg/rnl), 0·5 g of cyanogen bromide activated Sepharose 4B (Pharmacia Fine Chemicals AB, Uppsala, Sweden) was washed with 10 ml water. The dialysate was added to the Sepharose, made up to 10 ml with 0·1 M sodium bicarbonate, stirred slowly for 18 hours at 4°C, after which 3·35 mg of protein had bound to the Sepharose; 0·02 % sodium azide was added, and the conjugate was stored at 4 DC.
A 0'5-ml column of the Sepharose-antibody conjugate was prepared in a 2-ml syringe, washed with 3 ml 0·05 M sodium phosphate buffer, pH 7-4, primed with 1 mg polypeptide, and washed again with 3 ml buffer. The 2-ml syringe was connected to a 50-ml syringe containing fasting plasma + 0'02 % sodium azide, and 200 ml of plasma were dripped through the column at approximately 2 rnl/h, To test the capacity of the column to remove somatostatin, 20 ml of buffer containing 625 pg/rnl somatostatin standard was passed through the column and assayed.
Fasting plasma samples containing 2000 KIV/ml aprotinin from eight volunteers were doubly diluted in somatostatin-free plasma containing the same Erica Penman et al.
amount of aprotinin and assayed against a standard curve constructed in somatostatin-free plasma and aprotinin using EDTA in the diluent buffer.
EXTRACTION OF SOMATOSTATIN FROM
PLASMA
The plasma extraction method was essentially that described for ACTH (Rees et al., 1971) using Vycor glass (Mesh 140 Code 7930, Corning Glass International, Corning, New York, USA) which had been activated by heating to 600°C for one hour. Standard polystyrene tubes contained 3 ml horse serum (HS) (Wellcorne, H.S.3, UK) to which was added 2 ng of cyclic somatostatin; blanks contained 3 ml HS (some batches of which were found to contain up to 20 pg/rnl of immunoreactive somatostatin == 3 % of added standard), and plasma samples ranged in volume from 2 to 4 ml. 50 mg Vycor glass (the optimal amount for extraction of the added somatostatin) was added to each tube and mixed by rotation for 30 minutes. After centrifugation the supernatant was removed and the glass was washed with 3 ml of distilled water followed by 2 ml 1 M HCI. After removal of the HCl the somatostatin was eluted from the glass using 1 ml 80% methanol, the methanol supernatant was evaporated to dryness with oxygenfree nitrogen in a sand bath at 60°C, and the residue was reconstituted in 250 fLl diluent buffer and assayed immediately.
SOMATOSTATIN ASSAY
Of the diluent buffer containing extracted somatostatin 200 fLl was removed from the reconstituted tubes and doubly diluted in buffer nine times to give 100 fLl of standard in each tube; reconstituted blanks and sample tubes were similarly diluted four times. An unextracted standard curve was set up in diluent buffer with a range of somatostatin concentrations of 9-1250 pg/ml, To all tubes was added 200 ,...1 diluent buffer and 100 fLl antiserum at a final dilution of 1 :150 000. The tubes were incubated for 24 hours at 4 DC, 4 pg 125I-llTyr-somatostatin was added, and the tubes were incubated for a further 24 hours at 4°C. Control tubes with and without antibody were set up with each assay. Separation of bound from free 125I-llTyr-somatostatin was carried out by double antibody precipitation. Losses of standard somatostatin during extraction were routinely 40-60 %, and all plasma levels were corrected for these and the volume of plasma used.
COLLECTION OF PLASMA SAMPLES
Venous blood was collected into lithium heparin tubes (Searle LH/lO) containing 10000 KIV of aprotinin. The blood was centrifuged within IS minutes of collection, and the plasma was frozen im-mediately and stored at -70"C until extraction. Plasma samples were thawed immediately before extraction and centrifuged at 2000 rpm for 10 minutes. To determine a normal range for somatostatin, samples were collected as above from 40 normal volunteers on no medication, between 0830 and 0930 hours after an overnight fast (2400-0930 hours).
RECOVERY EXPERIMENTS 100 pgjml, 200 pgjml, and 400 pgjml of cyclic somatostatin standard were each added to 3 ml uf plasma and extracted. This experiment was repeated five times.
STABILITY OF SOMATOSTATIN IN PLASMA
Blood from five normal volunteers was collected into heparinised tubes with and without aprotinin. The samples were spun immediately, and one aliquot of plasma from each sample was flash-frozen within IS minutes. A second aliquot was left at room temperature for 24 hours and then flash-frozen. All the aliquots were measured in the same assay. Immunoreactive somatostatin (pg/ml) 
>.
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FFECT OF SAMPLE VOLUME
To shown whether the volume of plasma extracted affected the final corrected result, two plasma samples were each divided into aliquots of 1, 2, 3, and 4 ml and the aliquots were extracted separately.
Results
ANTIBODY CHARACTERISATION
The antiserum showed no cross-reaction with any of the hypothalamic, pituitary, or gastrointestinal proteins or peptides tested. Cross-reaction with the somatostatin analogues tested (Fig. I) demonstrated that neither the Nterminal glycine nor the C-terminal cysteine residue is required for antibody binding, suggesting that the antigenic site is directed towards the central part of the molecule containing the tryptophan residue. Fig. 1 Cross-reaction studies with analogues of somatostatin. Cyclic somatostatin (*-*), dihydrosomato- With our antiserum 125I-llTyr-somatostatin shows grea ter immunoreactivity than 1251_ 1 Tyr-somatostatin, as shown by the antibody dilution curves ( and the standard curves (Fig. 1) . In addition, a standard curve constructed from doubling dilutions of 125 1_ 11 Tyr-somatostatin is indistinguishable from that obtained with somatostatin standard using llTyr-somatostatin tracer, while a similar curve with 125I-1Tyr-somatostatin is not. Finally, 125]_ llTyr-somatostatin routinely gives a diluent blank of 8 % in our assay while that obtained with 1251-1Tyr-somatostatin is ] 5 %. We have therefore used a lactoperoxidase-iodinated preparation of 11 Tyr-somatostatin purified on ODS silica for all subsequent studies.
UNEXTRACTED SOMATOSTATIN ASSAY
Maximum sensitivity was achieved using 0'05 M sodium phosphate buffer at a pH of 7'4, with a protein concentration of 0·5 g HSA per 100 ml. The optimal incu bation conditions were as follows: 24 hours pre-incubation of standard or plasma with antibody at 4 "C followed by a further 24 hours at 4°C with tracer. Somatostatin-free plasma caused an apparently marked reduction in binding, which was only partly removed by the addition of EDTA and aprotinin alone or in combination ( Table) . Plasma samples did not show parallelism with a plasma standard curve when measured using this unextracted assay, and the levels obtained were much higher (50-100%) than those obtained with an extracted assay. Because of the decrease in binding observed in the presence of plasma the extracted assay system was obviously superior and was therefore used for all further studies.
SENSITIVITY
The limit of sensitivity of the unextracted buffer standard curve is 10 pg/rnl, defined as the precision at zero standard (Ekins and Newman, 1970) .
EXTRACTED SOMATOSTATIN ASSAY
Precision and reproducibility
The intra-assay coefficient of variation at a mean plasma level of 70 pg/rnl was 12% (n = 16). The inter-assay coefficient of variation at a mean level of 72 pg/ml was 15% (n = 10) and at a mean level of 272 pg/rnl it was 8·8 % (n = 5).
PARALLELISM
Parallelism between standard somatostatin and all extracted plasma samples was demonstrated by superimposability of plasma samples with standard curve using both log and legit/log plots (Rodbard and Lewald, 1970) (Fig. 8) . The lack of parallelism described by others Kronheim et al., 1976) was not observed.
Recovery experiments
The mean recovery of exogenous somatostatin (100, 200, and 400 pg/rnl) after extraction was 78~~, CV = 4%, n = 5.
Stability of somatostatin in plasma
Losses of up to 60% of the immunoreactive somatostatin in the plasma over 24 hours were found. However, this loss of activity did not appear to be reduced by aprotinin. The addition of aprotinin did not alter the values obtained.
Effect of sample volume
One plasma sample varied from 52 to 55 pg/rnl and the second from 49 to 55 pg/rnl in the different sample volumes assayed. The mean CV was 8·3 % (n = 7) with no upward or downward trend of the results with volume used.
Normal range of plasma immunoreactive somatostatin
Fasting immunoreactive somatostatin levels ranged from 17 to 81 pg/rnl, and levels were detectable in each of the 40 subjects tested. There was no apparent age or sex difference.
Discussion
The measurement of immunoreactive somatostatin in plasma requires a radioimmunoassay that is reliable, sensitive, and specific. Using an unextracted assay system, however, we found considerable and variable depression of binding of tracer somatostatin to antibody in the presence of plasma, thus confirming the findings of Arimura and colleagues (1975) . In agreement with the results of these authors, our unextracted assay system resulted in nonparallelism of plasma samples with standard somatostatin and yielded estimated fasting levels of 80-150 pg/rnl in normal subjects at 0900 hours. The interference in binding could be due to degradation of the tracer by enzymes present in the plasma or to interference with the second antibody separation step by some plasma component such as complement. Inclusion of aprotinin in the buffer should help to protect the tracer from enzymic degradation while the addition of EDTA should reduce the interference with the second antibody separation. However, even when both were added and the plasma had been treated by a highly specific method (that is, antibody adsorption) to remove all the somatostatin, we found that standard curves prepared in buffer and the treated plasma were not superimposable. Lastly, the presence of a somatostatin binding protein in the plasma has been suggested (Ogawa et al., 1977; Arimuraet al., 1978a; Diel and Schneider, 1978) . This, by combining with the somatostatin tracer, could prevent the binding of tracer to antibody, giving falsely high values. Further work is clearly required before the reasons for this interference in binding, which also occurs with other peptide hormones such as ACTH, MSH, and ,B-LPH (Gilkes et al., 1975; Jeffcoate et al., 1978) , can be fully elucidated. Because of these practical and theoretical problems, which could result in erroneous estimates of somatostatin levels, we elected to validate an extracted assay for somatostatin. Not only does this eliminate these non-specific effects but it also increases the effective sensitivity of the assay.
Both the sensitivity and reliability of the assay were greatly improved by increasing the immunoreactivity and stability of the labelled peptide. This was achieved by purifying the iodinated llTyr-somatostatin on ODS silica, which separates on the basis of hydrophobicity rather than ionic charge. The improved separation of iodinated from non-iodinated somatostatin means that only a very sm9.11 amount of purified undamaged label is added. Other workers have used "Tyr-somatostatin as tracer (Arirnura et al., 1975; Kronheim et al., 1976; Patel and Reichlin, 1978) , but with the antiserum that we have used llTyr-som".tostatin, in comparison with "Tyrsomatostatin, gave higher binding, lower blank values, and a more sensitive standard curve which was also indistinguishable from a buffer standard curve. II Tyr-sornatostatin was therefore used routinely. Methanol, in preference to acetone, was used to elute somatostatin (Rees et al., 1971) because there is likely to be less damage to the cyclic peptide during this procedure.
The stability of somatostatin in blood and plasma is unknown. In preliminary studies we have observed no reduction of somatostatin immunoreactivity if plasma is left at room temperature in aprotinin for up to 30 minutes. If left for 24 hours, however, there is a decrease in immunoreactivity of up to 60% and this occurs even with the addition of aprotinin. Clearly further work on the stability of somatostatin in blood and plasma is required, and although the addition of aprotinin may be unnecessary, it does not interfere with the assay or alter the values obtained.
We have compared the values obtained in human plasma and those obtained by other workers in man , dog , and rat (Berelowitz et al., 1978) . The values we have obtained in peripheral blood are much lower, and in man they are less by a factor of 10. There are clearly a number of possible reasons for these discrepancies. Tracer damage has been carefully eliminated by Kronheirn et al. (1977) , but the possible effects of a somatostatin binding protein which binds tracer (Arirnura et al., 1978a) are harder to eliminate without extraction. Using an extracted assay, these workers have, however, found somatostatin levels in the dog similar to those we have obtained in human plasma (Arimura et al., 1978b) . A further reason why laboratories may report different results is indicated in the comparison made of the different somatostatin preparations which show considerable differences in their immunoreactive potencies. While it is possible that different antibodies may have different affinities for the preparations tested, our data appear to be similar to those of Mclntosh et al. (1978) . Such differences in the potency of different preparations of synthetic somatostatin must clearly be taken into account when the data obtained from different laboratories are compared. Additionally, the immunoreactive potencies and any differences between them may bear little relation to the bioactivities of different preparations.
This assay has many potential uses. The physiological role of somatostatin in the control of human growth hormone and TSH secretion and of the gut hormones and renin in man is speculative, being based on the effects of exogenous administration. Clearly, the ability to measure circulating levels using a sensitive and valid assay should allow an attempt at direct analysis of these problems, particularly if the assay can be extended to the measurement of somatostatin in cerebrospinal fluid.
